Skip to NavigationSkip to content

GlaxoSmithKline acquires Sitari Pharmaceuticals after progress in coeliac disease

Published on 11/09/19 at 09:39am

Avalon Ventures has announced that it has entered into a definitive agreement with GSK for the acquisition of Sitari Pharmaceuticals for its novel treatment for coeliac disease.

San Diego-based Sitari was the first company formed under the GSK-Avalon venture collaboration back in 2013.

Coeliac disease is an autoimmune digestive disorder caused by intolerance to gluten, a protein found in barley, wheat and rye that disrupts and damages the intestine, interfering with the proper absorption of nutrients from food.

The enzymatic activity of transglutaminase 2 (TG2) is the culprit in triggering the inflammatory responses to gluten exposure in coeliac disease, and Sitari’s TG2 inhibitor has the potential to suppress intestinal inflammation.

Sitari CEO Jay Lichter stated: “Our collaboration with GSK has been overwhelmingly positive as we were able to rapidly launch a series of new companies based on promising scientific research, and we successfully advanced five programmes into preclinical studies for a variety of unmet medical needs.

“Sitari’s preclinical programme has the potential to become a medicine to help millions of patients with coeliac disease, and we are excited that GSK, a leader in developing innovative medicines, will be advancing the programme.”

John Lepore, Senior Vice President, added: “Over the last six years, GSK and Avalon have pioneered a unique biotech funding model designed to identify novel targets from top-tier academic labs and translate cutting-edge discoveries into promising clinical candidates.

“The current standard of care for coeliac disease is strict adherence to a gluten-free diet, but a significant number of patients still experience gastrointestinal symptoms and disease progression. TG2 inhibition could represent a new hope for coeliac disease patients.”

There are over 300 symptoms associated with coeliac disease and it is present in one in 100 people worldwide. Of those who follow a strict gluten-free diet, a massive 20% still do not respond positively. In America alone there are an estimated three million sufferers with roughly 80% of these being undiagnosed. If left unmanaged the condition can lead to intestinal cancers, type 1 diabetes, osteoporosis and more.

Nik Kiran

 

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches